

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Tarlatamab for treating extensive-stage small-cell lung cancer that has progressed after platinum-based chemotherapy ID6617

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During the scoping process, it was noted that small-cell lung cancer is associated with a history of heavy smoking and disproportionately affects people from more deprived communities. Stigma, lower health literacy, and financial challenges can make it harder for patients to seek care promptly, participate in clinical trials, or access treatment. A heavy smoking population is also often associated with multiple co-morbidities, frailty and poorer performance status.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee will consider any relevant equalities issues in its deliberations. Issues related to differences in prevalence or incidence of a disease cannot be addressed in this technology appraisal.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes were made to the scope. The committee will consider all relevant potential equality issues during the appraisal process.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No additional stakeholders related to potential equality issues were added.

Approved by Associate Director (name): Ian Watson

Date: 09 February 2026